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ercutaneous Valve
eplacement and Repair
iction or Reality?*
gor F. Palacios, MD, FACC
oston, Massachusetts
reater advances in the use of percutaneous techniques for
he treatment of coronary artery disease and cardiac non-
oronary interventions have occurred during the last few
ears. Among them, percutaneous techniques for the treat-
ent of stenotic valvular lesions were developed, and their
enefits were demonstrated in the treatment of most pa-
ients with pulmonary stenosis, rheumatic mitral stenosis,
nd tricuspid stenosis and in some patients with non-calcific
ortic stenosis (1,2). Even as percutaneous catheter ap-
roaches may be the procedure of choice for most patients
ith rheumatic mitral stenosis, they certainly are not for
ost elderly patients with calcific aortic stenosis (1,2).
lthough percutaneous techniques are the procedure of
hoice for the treatment of most stenotic valvular lesions,
pen heart surgery with valve replacement or repair is the
nly therapeutic alternative for the treatment of patients
ith symptomatic regurgitant valve lesions and for patients
ith calcific aortic stenosis (1–3).
See page 1652
Hundreds of thousands of patients in the U.S., including
large share of patients with congestive heart failure, might
enefit from heart valve repair or replacement. To date, the
urgical approach is the only option available for cardiac
alve replacement. It is expected that300,000 patients will
ndergo heart valve surgery in 2004 despite its invasiveness,
isk, and cost. However, valve replacement has limitations,
uch as surgical mortality, high-risk patient subgroups,
hronic anticoagulation, postoperative recovery, and late
ailure of bioprosthetic valves.
The future of percutaneous valve repair and replacement
epends on the development of collapsible and compressible
alve prostheses, transcatheter valve repair technologies,
nti-calcification treatment, and innovative valve suturing
echnologies. An integration of known technologies, includ-
ng balloon-expandable technology, balloon technology for
redilation and deployment, and bi- or tri-leaflet heart valve
esigns made from polymer or biologic material have the
otential to help in the development of percutaneous
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.w
From the Cardiac Unit, Department of Medicine, Massachusetts General Hospital
nd Harvard Medical School, Boston, Massachusetts.echniques for the treatment of regurgitant lesions. We can
ream of an ideal valve for percutaneous placement. This
alve should be available at variables sizes, should be
iocompatible, and should have excellent intrinsic proper-
ies and low profile. Finally, this valve should be able to be
utured into an expandable stent without losing its proper-
ies after crimping and re-expansion. Recently, percutane-
us transcatheter replacement of the pulmonic valve was
ntroduced by Bonhoeffer et al. (4,5), and percutaneous
alve replacement of calcific aortic stenosis was introduced
y Cribier et al. (6,7). This pioneering work by these two
nvestigators represents a milestone that opens a new era of
nterventional cardiology (4–7).
Mitral regurgitation is a common disease that is clinically
ignificant because of its detrimental effect on left ventricular
unction. Mitral regurgitation causes volume overload of the
eft ventricle and results in a vicious cycle. Volume overload
eads to remodeling, with left ventricular dilation and conse-
uent left ventricular dysfunction. Left ventricular dilation also
roduces abnormalities of mitral valve support and enlarge-
ent of the mitral annulus, which by themselves lead to
rogressive worsening of mitral regurgitation. The mitral valve
pparatus is a complex structure composed of the mitral
nnulus, the mitral valve leaflets, the chordae tendineae, the
apillary muscles, and the supporting of the left ventricular
all, the aorta, and the left atrium walls. Disease processes
ffecting any one of these components may result in dysfunc-
ion of the mitral valve apparatus, prolapsing leaflets, and
itral regurgitation. Whatever the etiology of mitral regurgi-
ation is, surgical mitral valve repair currently is the procedure
f choice (3). Initial attempts at percutaneous mitral valve
epair have recently been reported. Two procedures dealing
ith different components of the mitral valve apparatus have
een reported; the edge-to-edge repair and mitral valve annu-
oplasty using a coronary sinus device (8,9). The surgical
dge-to-edge repair has been shown to be an effective method
or repairing either structurally or functionally deficient mitral
alves. The catheter-based Evalve Cardiovascular Valve Repair
ystem (CVRS; Evalve Inc., Redwood City, California) is the
rst successful percutaneous endovascular adaptation of this
epair technique. The early clinical results with the Evalve
VRS are compelling. The phase I study of the Evalve
ardiovascular repair system, Endovascular Valve Edge-to-
dge Repair Study (EVEREST I), is currently underway in
he U.S. and will provide initial information on safety and
easibility of the procedure. Enrollment in the trial is ongoing,
ith the results for the first 10 patients presented at the
merican College of Cardiology’s late-breaking clinical trial
ession (New Orleans, Louisiana, March 2004). The clip was
afely deployed in all 10 patients without complications. A
eduction in mitral regurgitation to2 grades was achieved in
even patients. The clip was not released in the other three
atients, who underwent elective surgery. Ongoing studies
ith this technology will help to refine the technique and
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ability (9).
Future studies also are indicated to evaluate the potential
or adjunctive catheter-based annuloplasty systems. Mini-
ally invasive or even percutaneous valve repair has gained
ore momentum in recent months. Several companies are
orking on attractive instrumentation and devices to
chieve this goal. The knowledge of the anatomy and
athophysiology of the coronary sinus is an important
rerequisite of such devices. Multiple endovascular indirect
nnuloplasty (“sinoplasty”) systems as the one described by
aniu et al. (10) in this issue of the Journal are in preclinical
evelopment and also may offer adjunctive technology in the
reatment of patients with significant mitral regurgitation.
n this paper, the authors reported on the placement of a
ercutaneous mitral annuloplasty device that results in a
ignificant reduction in the severity of functional mitral
egurgitation associated with severe left ventricular dysfunc-
ion in a canine animal model of rapid pacing-induced heart
ailure with functional mitral regurgitation. Cinching of the
evice in the coronary sinus resulted in significant decrease
n mitral annulus diameter, mitral regurgitation jet area, and
itral regurgitation jet area-to-left atrium area ratio. This
echnique capitalizes on the relationship of the coronary
inus to the mitral annulus.
Nevertheless, there are some limitations in this study,
uch as the use of a single model of functional mitral
egurgitation. Also, the severity of mitral regurgitation was
nly modest. There is a need to apply this technique to
ther models of mitral regurgitation, such as those of
schemic mitral regurgitation. Furthermore, this device is
laced in the coronary sinus, and the circumflex artery is an
mportant surrounded structure of the coronary sinus.
herefore, it is important to determine whether this device
ould interfere with coronary blood flow, particularly in the
ircumflex artery. As described by the authors, the relation-
hip between the circumflex and the coronary sinus varies,
nd there is potential for device-induced compression of the
ircumflex artery.
A dramatic change is expected to occur during the next
ecade as the emergence of transcatheter heart valve repair
echniques significantly reduces the risk and cost associated
ith heart valve procedures. Animal and early humantudies indicate that nonsurgical techniques to valve replace-
ent and repair are feasible. These techniques already have
een applied safely to humans with artificial pulmonary
rtery trunks. More recently results from the approach to
ortic valve replacement and mitral valve repair in animals
nd humans are encouraging. Pulmonary valve replacement,
ortic valve replacement, and emerging techniques for
ercutaneous mitral valve repair recently have opened new
erspectives on transcatheter replacement and repair of
ardiac valves. Thus, percutaneous valve replacement and
epair is not fiction—it is a reality.
eprint requests and correspondence: Dr. Igor F. Palacios,
irector, Cardiac Catheterization Laboratories, Director of Inter-
entional Cardiology, Massachusetts General Hospital, Boston,
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